Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
Nephrology has benefited from conducting increasingly large high-quality trials in the last 5- 10 years. In addition to the long-standing known benefits of renin-angiotensin system inhibitors, we now have multiple pharmacotherapies that provide kidney and/or cardiovascular protection for certain typ...
Asıl Yazarlar: | Zhu, D, Staplin, N, Haynes, R, Herrington, W, Judge, P |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
Oxford University Press
2025
|
Benzer Materyaller
-
Kidney disease trials for the 21st century: innovations in design and conduct
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2019) -
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Yazar:: Mayne, K, ve diğerleri
Baskı/Yayın Bilgisi: (2024) -
Renoprotective effect of pentoxifylline in advanced chronic kidney disease
Yazar:: Chih-Chin Kao
Baskı/Yayın Bilgisi: (2015-01-01) -
Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
Yazar:: Preiss, D, ve diğerleri
Baskı/Yayın Bilgisi: (2022) -
The prevention and management of chronic kidney disease among patients with metabolic syndrome
Yazar:: Zhu, D, ve diğerleri
Baskı/Yayın Bilgisi: (2025)